Alembic obtains FDA nod for generic Cosopt
Dorzolamide hydrochloride and timolol maleate ophthalmic solution has a market value of roughly $80 million for the 12 months ended December 2020, according to IQVIA.
Alembic has received the Food and Drug Administration’s stamp of approval for dorzolamide hydrochloride and timolol maleate ophthalmic solution, 2% and 0.5%.
The product is the generic of Akorn’s Cosopt.
It is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
Dorzolamide hydrochloride and timolol maleate ophthalmic solution has a market value of roughly $80 million for the 12 months ended December 2020, according to IQVIA.